The Effect of Postoperative Antithrombin Supplementation on the Inflammatory and Coagulation Status of a Surgically Treated Patient With a Malignant Tumor in the Small Pelvis—Case Series

PMCID: PMC12177226

PMID: 40534446

DOI: 10.1002/cnr2.70260

Journal: Cancer reports (Hoboken, N.J.)

Publication Date: 2025-6-19

Authors: Lazović R, Šarenac O

Key Points

• Antithrombin supplementation can effectively normalize coagulation and inflammatory responses in complex surgical patients
• Observed 50-70% reduction in inflammatory markers (IL-6, CRP) within 4 postoperative days
• Careful monitoring and targeted AT supplementation may provide a strategic approach to managing hypercoagulable states in high-risk surgical patients

Summary

This study investigated the potential therapeutic benefits of antithrombin (AT) supplementation in patients undergoing complex surgical procedures for advanced colorectal cancer and acute pancreatitis. The research focused on addressing the hypercoagulable and inflammatory states that commonly occur in these high-risk surgical patients, particularly during the critical postoperative period.

The clinical intervention involved administering Kybernin (antithrombin) to three female patients in the first four postoperative days. Comprehensive laboratory monitoring revealed significant improvements in inflammatory markers and coagulation parameters. Notably, the AT supplementation effectively normalized leukocyte counts, reduced C-reactive protein (CRP) levels, modulated interleukin-6 and interleukin-10 responses, and stabilized coagulation markers like fibrinogen and D-dimer. The treatment demonstrated a remarkable ability to reestablish hemostatic balance and suppress the inflammatory cascade, potentially mitigating postoperative thrombotic and inflammatory risks.